Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Osteoporosis Health Center

Font Size

FDA Panel: Long-Used Osteoporosis Drug Too Risky

By Fran Lowry
Medscape Medical News

March 7, 2013 -- An FDA panel voted to stop recommending calcitonin salmon for the treatment of osteoporosis in women who are at least five years past menopause.

The committee voted 12-9 against continued marketing of the drug, citing lack of benefit and concerns about a cancer risk.

Calcitonin salmon has been used by women for years to treat osteoporosis.

In the U.S., calcitonin is marketed as Miacalcin and Fortical. It was approved in 1986 as an injection and in 1995 as a nasal spray. Calcitonin raises the amount of calcium in the bones while lowering calcium levels in the blood.

In 2012, the European Medicines Agency recommended that calcitonin salmon not be used to treat osteoporosis after determining that the risk of developing cancer was 2.4% higher in patients using the nasal spray than in those who took a placebo.

The nine committee members who voted to keep calcitonin on the market insisted it has a benefit, especially in the elderly and those with pain from vertebral fractures.

The 12 panelists who voted against it thought it had little benefit that might be outweighed by the cancer risk.

Cancer Risk Tips the Scale

William Cooper, MD, from Vanderbilt University School of Medicine in Nashville, Tenn., says his vote to stop marketing calcitonin salmon was swayed by the risk for cancer.

"The data that were presented to us today were not really all that compelling for benefit in the broad population of people with osteoporosis, but there is a fair amount of consistency in the data on cancer. Although it appeared to be a minor increase in risk, that really tipped the scales for me," he says.

Michael Collins, MD, from the National Institutes of Health in Bethesda, Md., also voted to stop marketing the drug.

"The cancer question, for better or for worse, has been raised. It's on the table. That weighed against limited [effectiveness] in the populations that have been studied. It's wishful thinking to say it could be effective in populations that haven't been studied, but there just aren't data to support this in my mind," he says.

Today on WebMD

Women working out and walking with weights
Reduce bone loss and build stronger muscles.
Chinese cabbage
Calcium-rich foods to add to your diet.
woman stretching
Get the facts on osteoporosis.
Porous bone
Causes, symptoms, risk factors, and treatment.
senior woman
Woman holding plate of brocolli
wrist xray
Superfood for Bones
mature woman
sunlight in hands
man and woman in front of xray
woman with dumbbells